The first licensed agent, talimogene laherparepvec (T-VEC), administered intratumorally, replicates within tumours to lyse infected cells while expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) to prime systemic immunity; in advanced melanoma it improved response rates and durability of benefit 156. Here, CSF2 is linked to melanoma.